IOVANCE BIOTHERAPEUTICS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.72 USD | +1.60% |
|
+3.80% | +44.40% |
Presenter SpeechPeter Lawson (Analysts)So first and foremost for us at Barclays down in Miami,...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Iovance Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company develops and delivers tumor infiltrating lymphocyte (TIL), therapies for patients with solid tumor cancers. Its lead product candidate, Amtagvi (lifileucel), is a tumor-derived autologous T cell immunotherapy indicated for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor. The Company also marketing Proleukin (aldesleukin), aninterleukin-2, or IL-2, product used in the Amtagvi treatment regimen. Its development pipeline includes multicenter trials of TIL cell therapies in additional treatment settings for solid tumor cancers. Amtagvi and Proleukin are part of a treatment regimen that also includes lymphodepletion. The Company is also developing next generation therapies using TIL, such as genetically modified TIL cell therapy.
Calendar
2024-05-06
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
11.54
USD
Average target price
26
USD
Spread / Average Target
+125.30%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +44.40% | 3.22B | |
| -19.59% | 10.67B | |
| -35.49% | 2.09B | |
| -17.21% | 2.04B | |
| -28.75% | 1.46B | |
| +19.01% | 1B | |
| -4.37% | 734M | |
| -36.67% | 391M | |
| -46.04% | 379M | |
| +13.32% | 343M |
- Stock Market
- Equities
- IOVA Stock
- News Iovance Biotherapeutics, Inc.
- Transcript : Iovance Biotherapeutics, Inc. Presents at Barclays Global Healthcare Conference 2022, Mar-17-2022 10
